Top-News
Donnerstag,
06.08.2015 12:35
von
PR Newswire
| Aufrufe: 438
Oncolytics Biotech® Inc. Announces 2015 Second Quarter Results
Pipette und Proben (Symbolbild).
© alvarez / E+ / Getty Images
http://www.gettyimages.de
PR Newswire
CALGARY, Aug. 6, 2015
CALGARY, Aug. 6, 2015 /PRNewswire/ - Oncolytics Biotech® Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the second quarter ended June 30, 2015.
"Subsequent to quarter end we announced compelling overall, one- and two-year survival data from the REO 017 study in patients with advanced pancreatic cancer treated with gemcitabine and REOLYSIN®," said Dr. Brad Thompson, President and CEO of Oncolytics. "During the quarter we also added to our growing body of evidence that REOLYSIN® contributes to the upregulation of PD-1 and PD-L1 and so may play a role in immunotherapeutic treatment of cancer."
Selected Highlights
Since April 1, 2015, selected highlights announced by the Company include:
Clinical Program
- Presentation of final data from a single arm clinical study examining the use of REOLYSIN® in combination with gemcitabine in patients with advanced pancreatic cancer (REO 017), which showed an increase in median overall survival, as well as an approximate two-fold increase in one-year survival rates, and a five-fold increase in two-year survival rates when compared to gemcitabine therapy alone as seen in historical data;
- An update on the planned registration program for REOLYSIN® including an initial focus on two indications: the neoadjuvant treatment of muscle-invasive bladder cancer and the treatment of glioblastoma;
- Activation of an Investigational New Drug Application containing the protocol titled "MC1472: Phase 1 Study of Replication Competent Reovirus (REOLYSIN®) in Combination with GM-CSF in Pediatric Patients with Relapsed or Refractory Brain Tumors";
- Presentation of data showing up regulation of PD-1 and PD-L1 from a single arm clinical study examining the use of REOLYSIN® in patients with primary glioblastomas or brain metastases (REO 013b) at the Royal Society of Medicine's Immuno-oncology: Using the Body's Own Weapons conference, held in London, UK;
Regulatory
- Granting of Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for REOLYSIN® in the treatment of gastric cancer and malignant gliomas;
- Granting of Orphan Drug Designation by the European Medicines Agency for REOLYSIN® in the treatment of pancreatic cancer;
Basic Research
- Presentation of preclinical data at the 9th International Conference on Oncolytic Virus Therapeutics in Boston, MA, including findings around REOLYSIN®'s mechanism of action and its potential in new indications including chronic lymphocytic leukemia;
- Presentation of clinical and preclinical data at the 2015 Immune Checkpoint Inhibitors meeting in Boston, MA, including content showing the combination of REOLYSIN®, GM-CSF, anti-PD-1 and anti-CTLA-4 improved survival in immune competent mice versus REOLYSIN® and GM-CSF alone, and REOLYSIN® and GM-CSF plus either one of the checkpoint inhibitors alone;
- A series of presentations made by the Company's research collaborators at the American Association for Cancer Research Annual Meeting held in Philadelphia, PA covering preclinical research in a range of indications, with a variety of treatment combinations including REOLYSIN®;
Corporate
- Linda Hohol resigned from the Board of Directors of the Company effective August 5, 2015. Ms. Hohol has served as a Director since June 2014; and
Financial
- At June 30, 2015 the Company reported $32.1 million in cash, cash equivalents and short-term investments. At August 5, 2015, the Company had approximately $31.6 million in cash, cash equivalents and short-term investments.
| ONCOLYTICS BIOTECH INC. | |||||
| INTERM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION | |||||
| (unaudited) | |||||
| | | | |||
| | June 30, 2015 $ | December 31, 2014 $ | |||
| Assets | | | |||
| Current assets | | | |||
| Cash and cash equivalents | 30,018,217 | | 14,152,825 | | |
| Short-term investments | 2,060,977 | | 2,031,685 | | |
| Accounts receivable | 61,261 | | 191,751 | | |
| Prepaid expenses | 581,468 | | 291,553 | | |
| Total current assets | 32,721,923 | | 16,667,814 | | |
| | | | | | |
| Non-current assets | | | |||
| Property and equipment | 467,690 | | 525,376 | | |
| Total non-current assets | 467,690 | | 525,376 | | |
| | | | |||
| Total assets | 33,189,613 | | 17,193,190 | | |
| | | | | | |
| Liabilities And Shareholders' Equity | | | |||
| Current Liabilities | | | |||
| Accounts payable and accrued liabilities | 3,058,476 | | 3,373,997 | | |
| Total current liabilities | 3,058,476 | | 3,373,997 | | |
| | | | |||
| Shareholders' equity | | | |||
| Share capital | | | |||
| | Authorized: unlimited | | | ||
| | June 30, 2015 – 117,710,372 | | | ||
| | December 31, 2014 - 93,512,494 | 261,015,977 | | 237,657,056 | |
| Contributed surplus | 26,019,074 | | 25,848,429 | | |
| Accumulated other comprehensive loss | 464,517 | | 280,043 | | |
| Accumulated deficit | (257,368,431) | | (249,966,335) | | |
| Total shareholders' equity | 30,131,137 | | 13,819,193 | | |
| Total liabilities and equity | 33,189,613 | | 17,193,190 | | |
| ONCOLYTICS BIOTECH INC. | |||||||||
| INTERIM CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS | |||||||||
| (unaudited) | |||||||||
| | | | | | |||||
| | Three Month Period Ending June 30, 2015 | Three Month Period Ending June 30, 2014 | Six Month Werbung Mehr Nachrichten zur ONCOLYTICS BIOTECH Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE (Mit der Bestellung akzeptierst du die Datenschutzhinweise) -1  Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink. Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte. Andere Nutzer interessierten sich auch für folgende News | ||||||
